AE, adverse effects; ALT, alanine transaminase; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; CTP, Child-Turcotte-Pugh classification; ELF, enhanced liver fibrosis; GI, gastrointestinal; GLP-1, glucagon-like peptide 1; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OCA, obeticholic acid; RCT, randomized controlled trial. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.